May 29 (Reuters) - Invitrogen Corp. IVGN.O, which provides tools and cultures used in genetic research and drug production, and Takara Bio Inc.’s unit Clontech Laboratories Inc. said they settled their patent litigation following a jury decision last week in federal district court in Greenbelt, Maryland.
As part of the settlement, Clontech has agreed that Invitrogen patents on RNase H minus reverse transcriptase (RT) are valid and enforceable.
Clontech has discontinued sales of its RNase H minus RT products, including its PowerScript products, for the life of the patents, the companies said in a statement.
(Reporting by Dilipp S. Nag in Bangalore)
((Editing by Deepak Kannan;Reuters Messaging: firstname.lastname@example.org; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: INVITROGEN PATENT/
C Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2671